Drug intelligence / Profile preview

Hepos

Development stage: Unknown
Lead developer: Cho-A Pharm
Modality: Small Molecules
Administration: Oral

Overview

**Hepos** is a Cho-A Pharmaceutical oral over-the-counter fixed-dose liver-disease adjunct product. It contains **L-arginine, betaine, betaine hydrochloride, and citric acid monohydrate** and is supplied as an oral liquid/syrup in ampoule, pouch, and bottle presentations. Cho-A markets it for adjunctive treatment of liver diseases; the product was originally launched in 1997 as Hepos and was subsequently renewed as Hepatos Syrup.

Brand names: Hepatos SyrupHeposHepos Syrup

Beyond the preview

Go deeper on Hepos.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepos.

Explore the full profile